Consequence of the tumor-associated conversion to cyclin D1b

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Cyclin D1b, a variant of cyclin D1, is linked to tumor progression and poor patient outcomes.
• The molecular mechanisms driving cyclin D1b's oncogenic potential remain largely unknown.

Purpose of the Study:

• To elucidate the molecular basis of cyclin D1b's role in cancer.
• To investigate the functional and transcriptional regulatory roles of cyclin D1b in vivo.
• To identify potential therapeutic targets for cyclin D1b-driven tumors.

Main Methods:

• Generation of novel genetic models to switch between cyclin D1 and cyclin D1b expression.
• Comprehensive analysis of developmental phenotypes and transcriptional regulation.
• In vivo studies of cellular transformation and tumor growth promotion.
• Exploration of links between cyclin D1b and DNA damage/PARP1 pathways.

Main Results:

• Cyclin D1b exhibits overlapping but distinct functions compared to cyclin D1, highlighting its unique regulatory roles.
• Cyclin D1b acts as an oncogene, inducing cellular transformation and promoting tumor growth in cooperation with other oncogenes.
• Unexpected connections between cyclin D1b and DNA damage response pathways, including PARP1, were uncovered.

Conclusions:

• This study defines the impact of cyclin D1b expression on cellular function and establishes it as an oncogene.
• Novel therapeutic strategies targeting the DNA damage/PARP1 network can suppress cyclin D1b-dependent tumor growth.
• The findings provide pre-clinical evidence for targeting cyclin D1b-driven cancers.